EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitKlinische Studie

Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review

Jinxia Zhao, Xiaoying Zhang, Yime Zhang, Xinyi Li, Hui Wei, Yinji Jin, Rui Liu, Zhaohua Li, Wei Guo, Zhenqing Wang, Yue Guo, Yunxia Xia und 11 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2025.12.014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Jinxia Zhao und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China; Beijing Key Laboratory of Clinical Evaluation of Cardiov…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Nephritis, Antigens, CD19, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to evaluate the efficacy and safety of IM19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell, in patients with refractory systemic lupus erythematosus (SLE), with a particular focus on lupus nephritis (LN). METHODS: This is an open-label, single-arm clinical trial. IM19 was administered following lymphodepletion. Repeated renal biopsies were performed at day 180. Single-cell RNA sequencing on peripheral blood mononuclear cells was performed pre- and 180-day post-CAR-T infusion. A literature search on the efficacy of CAR T-cell therapy in LN in PubMed database was conducted. RESULTS: Six patients with refractory SLE and renal involvement were enrolled. IM19 therapy was well tolerant, with mild cytokine release syndrome occurring in 4 patients. The median Systemic Lupus Erythematosus Disease Activity Index-2000 score decreased from 12 (range, 10-24) to 4 (range, 2-8) at day 90, and remained stable at 5 (range, 2-6) at day 180. The renal responses were heterogeneous with 2 complete responders, 2 partial responders, and 2 nonresponders. Repeated renal biopsies showed no B-cell infiltration, but dominant chronic changes and podocytopathies post-CAR-T therapy. A mini-review demonstrated that the renal complete response rate of CAR-T therapy was 72.4%, and advanced age was associated with suboptimal response. Single-cell analysis confirmed B-cell reconstitution in 3/6 patients. CONCLUSIONS: IM19 CAR T-cell therapy demonstrated a favourable safety profile and clinically meaningful systemic improvement. Responses to CAR-T therapy in LN were variable. Chronic renal manifestations, podocytopathy, and ageing were associated with suboptimal therapeutic outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicLupus NephritisAntigens, CD19Immunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric AntigenHumansPilot ProjectsFemaleAdultMaleMiddle AgedTreatment OutcomeYoung AdultKidney

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China; Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and…
  • Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China.
  • Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China.
  • Department of Pathology, Peking University Third Hospital, Beijing, China.
  • Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
  • Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, J., Zhang, X., Zhang, Y., Li, X., Wei, H., Jin, Y., Liu, R., Li, Z., Guo, W., Wang, Z., Guo, Y., Xia, Y., Yu, Y., Liu, H., Zeng, L., Shu, Q., Sun, J., Tian, Y., Ding, Y., …, & Mu, R. (2026). Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.12.014

Vancouver

Zhao J, Zhang X, Zhang Y, Li X, Wei H, Jin Y, et al. Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.12.014

BibTeX
@article{Zhao2026,
  author = {Zhao, Jinxia and Zhang, Xiaoying and Zhang, Yime and Li, Xinyi and Wei, Hui and Jin, Yinji and Liu, Rui and Li, Zhaohua and Guo, Wei and Wang, Zhenqing and Guo, Yue and Xia, Yunxia and Yu, Yang and Liu, Haijing and Zeng, Lin and Shu, Qiang and Sun, Jinlian and Tian, Yang and Ding, Yanping and He, Ting and Lu, Xin'an and Sun, Lin and Mu, Rong},
  title = {Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2025.12.014}
}
Kostenlos starten →